ANDIndenture • February 5th, 2002 • Us Oncology Inc • Services-specialty outpatient facilities, nec • New York
Contract Type FiledFebruary 5th, 2002 Company Industry Jurisdiction
Exhibit 10.2 ================================================================== ============== AMENDED AND RESTATED PARTICIPATION AGREEMENT Dated as of February 1, 2002Participation Agreement • March 29th, 2002 • Us Oncology Inc • Services-specialty outpatient facilities, nec • North Carolina
Contract Type FiledMarch 29th, 2002 Company Industry Jurisdiction
RECITALSNote Purchase Agreement • March 28th, 2001 • Us Oncology Inc • Services-specialty outpatient facilities, nec • Texas
Contract Type FiledMarch 28th, 2001 Company Industry Jurisdiction
EXHIBIT 2.1 AGREEMENT AND PLAN OF MERGERMerger Agreement • December 15th, 1998 • American Oncology Resources Inc /De/ • Services-specialty outpatient facilities, nec • Delaware
Contract Type FiledDecember 15th, 1998 Company Industry Jurisdiction
RECITALSLoan Agreement • March 28th, 2001 • Us Oncology Inc • Services-specialty outpatient facilities, nec • North Carolina
Contract Type FiledMarch 28th, 2001 Company Industry Jurisdiction
EXHIBIT 10.3 TERMINATION AGREEMENT This Termination Agreement dated effective June 30, 1999, is made by and between ILEX ONCOLOGY, INC., a Delaware corporation ("ILEX"), and PRN RESEARCH, INC., a Texas corporation ("PRN"). W I T N E S S E T H:...Termination Agreement • August 16th, 1999 • Us Oncology Inc • Services-specialty outpatient facilities, nec
Contract Type FiledAugust 16th, 1999 Company Industry
EXHIBIT 4 REGISTRATION RIGHTS AGREEMENT Dated as of February 1, 2002Registration Rights Agreement • February 5th, 2002 • Us Oncology Inc • Services-specialty outpatient facilities, nec • New York
Contract Type FiledFebruary 5th, 2002 Company Industry Jurisdiction
EXHIBIT 2 US ONCOLOGY, INC. $175,000,000 9 5/8% Senior Subordinated Notes due 2012 PURCHASE AGREEMENTPurchase Agreement • February 5th, 2002 • Us Oncology Inc • Services-specialty outpatient facilities, nec • New York
Contract Type FiledFebruary 5th, 2002 Company Industry Jurisdiction
EXHIBIT 10.1 THIRD AMENDED AND RESTATED LOAN AGREEMENTLoan Agreement • March 23rd, 1998 • American Oncology Resources Inc /De/ • Services-specialty outpatient facilities, nec • North Carolina
Contract Type FiledMarch 23rd, 1998 Company Industry Jurisdiction
amongCredit Agreement • March 29th, 2002 • Us Oncology Inc • Services-specialty outpatient facilities, nec • New York
Contract Type FiledMarch 29th, 2002 Company Industry Jurisdiction
CONFIDENTIALSeverance Agreement • March 24th, 1999 • American Oncology Resources Inc /De/ • Services-specialty outpatient facilities, nec
Contract Type FiledMarch 24th, 1999 Company Industry
Exhibit 10.3 AMENDED AND RESTATED CREDIT AGREEMENT Dated as of February 1, 2002Credit Agreement • March 29th, 2002 • Us Oncology Inc • Services-specialty outpatient facilities, nec • North Carolina
Contract Type FiledMarch 29th, 2002 Company Industry Jurisdiction
andRights Agreement • June 2nd, 1997 • American Oncology Resources Inc /De/ • Services-specialty outpatient facilities, nec • Delaware
Contract Type FiledJune 2nd, 1997 Company Industry Jurisdiction
RECITALSLoan Agreement • November 14th, 1996 • American Oncology Resources Inc /De/ • Services-specialty outpatient facilities, nec • North Carolina
Contract Type FiledNovember 14th, 1996 Company Industry Jurisdiction
EXHIBIT 2.2 CERTAIN INFORMATION IN THIS EXHIBIT IS SUBJECT TO A REQUEST FOR CONFIDENTIAL TREATMENT. IN ACCORDANCE WITH RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, SUCH INFORMATION HAS BEEN OMITTED AND FILED SEPARATELY WITH THE...Purchase Agreement • May 9th, 1997 • American Oncology Resources Inc /De/ • Services-specialty outpatient facilities, nec • Texas
Contract Type FiledMay 9th, 1997 Company Industry Jurisdiction
EXHIBIT 10.18 US ONCOLOGY, INC. CHIEF EXECUTIVE OFFICER STOCK OPTION PLAN AND AGREEMENT This Stock Option Plan and Agreement (this "Agreement") between US Oncology, Inc., a Delaware corporation (the "Company"), and R. Dale Ross ("Optionee") sets forth...Stock Option Agreement • March 28th, 2001 • Us Oncology Inc • Services-specialty outpatient facilities, nec • Texas
Contract Type FiledMarch 28th, 2001 Company Industry Jurisdiction
US ONCOLOGYEmployment Agreement • March 30th, 2000 • Us Oncology Inc • Services-specialty outpatient facilities, nec • Texas
Contract Type FiledMarch 30th, 2000 Company Industry Jurisdiction
amongCredit Agreement • March 23rd, 1998 • American Oncology Resources Inc /De/ • Services-specialty outpatient facilities, nec • North Carolina
Contract Type FiledMarch 23rd, 1998 Company Industry Jurisdiction
EXHIBIT 10.1 FOURTH AMENDED AND RESTATED LOAN AGREEMENTLoan Agreement • August 16th, 1999 • Us Oncology Inc • Services-specialty outpatient facilities, nec • North Carolina
Contract Type FiledAugust 16th, 1999 Company Industry Jurisdiction
RECITALSCredit Agreement • March 21st, 2003 • Us Oncology Inc • Services-specialty outpatient facilities, nec • North Carolina
Contract Type FiledMarch 21st, 2003 Company Industry Jurisdiction
BY AND AMONGMaster Transaction Agreement • May 9th, 1997 • American Oncology Resources Inc /De/ • Services-specialty outpatient facilities, nec • Texas
Contract Type FiledMay 9th, 1997 Company Industry Jurisdiction
PARTICIPATION AGREEMENT Dated as of December 30, 1997 among AOR SYNTHETIC REAL ESTATE, INC., as the Construction Agent, as the Lessee and as a Tranche A Guarantor, AMERICAN ONCOLOGY RESOURCES, INC., as the Guarantor and as a Tranche A Guarantor, THE...Participation Agreement • March 23rd, 1998 • American Oncology Resources Inc /De/ • Services-specialty outpatient facilities, nec • North Carolina
Contract Type FiledMarch 23rd, 1998 Company Industry Jurisdiction
March 31, 2001 Lloyd K. Everson, M.D. US Oncology, Inc. 16825 Northchase Drive, Suite 1300 Houston, Texas 77060 Re: Termination of Employment Agreement Dear Dr. Everson: In connection with the termination of your current employment agreement and the...Termination of Employment Agreement • May 14th, 2001 • Us Oncology Inc • Services-specialty outpatient facilities, nec
Contract Type FiledMay 14th, 2001 Company Industry
SECTION 2. AMENDMENTS TO OPERATIVE AGREEMENTSOperative Agreements • March 21st, 2003 • Us Oncology Inc • Services-specialty outpatient facilities, nec • Utah
Contract Type FiledMarch 21st, 2003 Company Industry Jurisdiction
PARENT STOCK OPTION AGREEMENTStock Option Agreement • December 15th, 1998 • American Oncology Resources Inc /De/ • Services-specialty outpatient facilities, nec • Delaware
Contract Type FiledDecember 15th, 1998 Company Industry Jurisdiction
EXHIBIT 2.2 COMPANY STOCK OPTION AGREEMENTStock Option Agreement • December 15th, 1998 • American Oncology Resources Inc /De/ • Services-specialty outpatient facilities, nec • Delaware
Contract Type FiledDecember 15th, 1998 Company Industry Jurisdiction
US ONCOLOGY HOLDINGS, INC. $425,000,000 Senior Unsecured Floating Rate Toggle Notes Due 2012 Registration Rights AgreementRegistration Rights Agreement • March 16th, 2007 • Us Oncology Inc • Services-specialty outpatient facilities, nec • New York
Contract Type FiledMarch 16th, 2007 Company Industry JurisdictionUS Oncology Holdings, Inc., a corporation organized under the laws of Delaware (the “Issuer”), which is the parent of US Oncology, Inc., a corporation organized under the laws of Delaware, proposes to issue and sell to certain purchasers (the “Initial Purchasers”), for whom you (the “Representatives”) are acting as representatives, $425,000,000 principal amount of its Senior Unsecured Floating Rate Toggle Notes Due 2012 (the “Securities”), upon the terms set forth in the Purchase Agreement between the Issuer and the Representatives, dated March 1, 2007 (the “Purchase Agreement”), relating to the initial placement (the “Initial Placement”) of the Securities. To induce the Initial Purchasers to enter into the Purchase Agreement and to satisfy a condition to your obligations thereunder, the Issuer agrees with you for your benefit and the benefit of the holders from time to time of the Securities (including the Initial Purchasers) (each a “Holder” and, collectively, the “Holders”), as foll
ContractIncremental Facility Amendment • July 14th, 2006 • Us Oncology Inc • Services-specialty outpatient facilities, nec • New York
Contract Type FiledJuly 14th, 2006 Company Industry JurisdictionINCREMENTAL FACILITY AMENDMENT AND AMENDMENT NO. 3 (this “Amendment”) dated as of July 10, 2006, to the CREDIT AGREEMENT dated as of August 20, 2004, as amended as of March 17, 2005, and November 15, 2005 (the “Credit Agreement”), among US ONCOLOGY HOLDINGS, INC., a Delaware corporation (“Holdings”), US ONCOLOGY, INC., a Delaware corporation (the “Borrower”), the LENDERS party thereto, JPMORGAN CHASE BANK, N.A., as Administrative Agent and Collateral Agent, WACHOVIA BANK, NATIONAL ASSOCIATION, as Syndication Agent, and CITICORP NORTH AMERICA, INC., as Documentation Agent.
AGREEMENT AND PLAN OF MERGER AMONG OILER HOLDING COMPANY, OILER ACQUISITION CORP. AND US ONCOLOGY, INC. Dated as of March 20, 2004Merger Agreement • March 22nd, 2004 • Us Oncology Inc • Services-specialty outpatient facilities, nec • Delaware
Contract Type FiledMarch 22nd, 2004 Company Industry JurisdictionTHIS AGREEMENT AND PLAN OF MERGER, dated as of March 20, 2004 (this “Agreement”), is made and entered into by and among OILER HOLDING COMPANY, a Delaware corporation (“Parent”), OILER ACQUISITION CORP., a Delaware corporation (“Acquisition”), and US ONCOLOGY, INC., a Delaware corporation (the “Company”).
US ONCOLOGY HOLDINGS, INC. $425,000,000 Senior Unsecured Floating Rate Toggle Notes Due 2012 Purchase AgreementPurchase Agreement • March 16th, 2007 • Us Oncology Inc • Services-specialty outpatient facilities, nec • New York
Contract Type FiledMarch 16th, 2007 Company Industry JurisdictionUS Oncology Holdings, Inc., a corporation organized under the laws of Delaware (the “Issuer”), which is the parent of US Oncology, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to issue and sell to the several parties named in Schedule I hereto (the “Initial Purchasers”), for whom you (the “Representatives”) are acting as representatives, $425,000,000 principal amount of its Senior Unsecured Floating Rate Toggle Notes Due 2012 (the “Securities”). The Securities are to be issued under an indenture (the “Indenture”), to be dated as of March 13, 2007, between the Issuer and LaSalle Bank National Association, as trustee (the “Trustee”). The Securities have the benefit of a Registration Rights Agreement (the “Registration Rights Agreement”), dated as of the date hereof, between the Issuer and the Initial Purchasers, pursuant to which the Issuer has agreed to register the Securities under the Act subject to the terms and conditions therein specified. To t
US ONCOLOGY HOLDINGS, INC. UNIT AWARD AGREEMENT UNDER THE 2008 LONG-TERM CASH INCENTIVE PLANUnit Award Agreement • May 14th, 2008 • Us Oncology Inc • Services-specialty outpatient facilities, nec
Contract Type FiledMay 14th, 2008 Company IndustryThis Unit Award Agreement (this “Agreement”) is made as of , 20 (the “Grant Date”), between US Oncology Holdings, Inc., a Delaware corporation (the “Company”), and (the “Participant”).
ContractCredit Agreement • December 4th, 2007 • Us Oncology Inc • Services-specialty outpatient facilities, nec • New York
Contract Type FiledDecember 4th, 2007 Company Industry JurisdictionAMENDMENT NO. 6 dated as of November 30, 2007 (this “Amendment”), among US ONCOLOGY HOLDINGS, INC. (“Holdings”), US ONCOLOGY, INC. (the “Borrower”), the Subsidiary Loan Parties (as defined in the Credit Agreement (as defined below)), the Lenders party hereto and JPMORGAN CHASE BANK, N.A., as Administrative Agent.
ContractCredit Agreement • March 29th, 2005 • Us Oncology Inc • Services-specialty outpatient facilities, nec • New York
Contract Type FiledMarch 29th, 2005 Company Industry JurisdictionAMENDMENT NO. 1 dated as of March 17, 2005 (this “Amendment”), to the CREDIT AGREEMENT (the “Credit Agreement”) dated as of August 20, 2004, among US ONCOLOGY HOLDINGS, INC.(“Holdings”), US ONCOLOGY, INC. (the “Borrower”), the LENDERS party thereto, JPMORGAN CHASE BANK, N.A., as Administrative Agent and Collateral Agent, WACHOVIA BANK, NATIONAL ASSOCIATION, as Syndication Agent, and CITICORP NORTH AMERICA, INC., as Documentation Agent.
SECOND SUPPLEMENTAL INDENTURE Dated as of February 15, 2011 between US ONCOLOGY, INC., and WILMINGTON TRUST FSB, as Trustee to the INDENTURE Dated as of June 18, 2009 Among US ONCOLOGY, INC., THE SUBSIDIARY GUARANTORS NAMED THEREIN and WILMINGTON...Second Supplemental Indenture • February 17th, 2011 • Us Oncology Inc • Services-specialty outpatient facilities, nec • New York
Contract Type FiledFebruary 17th, 2011 Company Industry JurisdictionTHIS SECOND SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of February 15, 2011, between US Oncology, Inc., a Delaware corporation (the “Company”), and Wilmington Trust FSB, as trustee (together with its successors and assigns, in such capacity, the “Trustee”).
AMENDMENT NO. 1 TO THE RIGHTS AGREEMENT OF US ONCOLOGY, INC.Rights Agreement • March 22nd, 2004 • Us Oncology Inc • Services-specialty outpatient facilities, nec • Delaware
Contract Type FiledMarch 22nd, 2004 Company Industry JurisdictionThis Amendment No. 1, dated as of March 20, 2004, amends the Rights Agreement dated as of May 29, 1997 (as amended and in effect from time to time, the “Rights Agreement”), between US Oncology, Inc., a Delaware corporation (the “Corporation”), and American Stock Transfer & Trust Company, as Rights Agent (the “Rights Agent”). Terms not otherwise defined herein shall have the meanings assigned to such terms in the Rights Agreement.